Cedara wins some, loses some
Toronto-based Cedara introduced a new orthopedics desk application July 16. Earlier in the month, the company announced a deal with a major Chinese OEM to supply a user interface for its x-ray products. The good news came, however, on the heels of an
Toronto-based Cedara introduced a new orthopedics desk application July 16. Earlier in the month, the company announced a deal with a major Chinese OEM to supply a user interface for its x-ray products. The good news came, however, on the heels of an announcement that the company has been delisted from the Nasdaq effective July 7.
The newly released Cedara OrthoWorks is a suite of desktop and Web server software solutions designed for orthopedic surgeons. The product allows instant access to digital patient images, surgical planning aids, measurement tools, and a library of digital prosthetic templates.
The product release followed a July 7 announcement that Shan Dong XinHua Medical, one of the largest medical equipment manufacturers in China, will integrate its new x-ray systems with Cedara's I-Acquire DR universal acquisition console application. The Cedara technology allows the acquisition of images from multiple digital detectors and x-ray generators from a single user interface.
Cedara stock is now being traded on the OTC Bulletin Board in the wake of its delisting from the Nasdaq. The move became necessary when Cedara was not able to meet the minimum shareholders' equity requirement. The company's listing on the Toronto Stock Exchange, where most of its shares have historically traded, was not affected.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
